Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Background Dosing of renin–angiotensin–aldosterone system inhibitors (RAASi) may be modified to manage associated hyperkalemia risk; however, this approach could adversely affect cardiorenal outcomes. This study investigated real‐world associations of RAASi dose, hyperkalemia, and adverse clinical o...

Full description

Bibliographic Details
Main Authors: Cecilia Linde, Ameet Bakhai, Hans Furuland, Marc Evans, Phil McEwan, Daniel Ayoubkhani, Lei Qin
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
chronic kidney disease
heart failure
hyperkalemia
major adverse cardiac event
renin–angiotensin system
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.012655

Similar Items

Similar Items